Cord blood transplant with added white blood cells for high-risk leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new way to do cord blood transplants for people with high-risk leukemia. It adds extra white blood cells (granulocytes) to boost the immune system and help fight the disease, with the goal of improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a suitable cord blood unit available for transplant.
- You must be between 16 and 55 years old.
- You have acute myeloid leukemia (AML) or a related condition with high-risk features, such as certain genetic changes or not achieving remission after initial treatment.
- Your bone marrow should show limited leukemia cells (less than 10% blasts) or be discussed with the trial team if higher.
- You need to be fit enough for transplant, with good heart, lung, kidney, and liver function, and be able to care for yourself (ECOG performance status 0 or 1).
- If you or your partner can have children, you must agree to use highly effective contraception during treatment and for 12 months after transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.